We were involved in the development and in the evaluation of the psychoeducational program MOSES about 20 years ago; therefore, we can appreciate the tremendous work of the SMILE study group in preparing and evaluating the SMILE program.
| WHICH OUTCOME MEASURES ARE SUITABLE?
The aims of each module of MOSES and SMILE are explicitly defined in the written materials for trainers and patients. The most important are improving knowledge and coping with epilepsy, including the expression of feelings. However, knowledge and coping were assessed neither as primary nor as secondary outcome measures in the SMILE RCT. 1 Furthermore, this makes a comparison with the MOSES evaluation study impossible. It is noteworthy that the SMILE authors performed in-depth interviews with participants of the SMILE study and concluded, "A brief group self-management intervention increased knowledge and confidence in managing epilepsy." 4, 5 In accordance with the MOSES RCT, the SMILE RCT did not find effects on quality of life. The MOSES study used a generic quality of life instrument (Short-Form Health Survey-36). However, the subscales Well-Being and Energy-Fatigue of the Quality of Life in Epilepsy-31 have the same core as corresponding subscales of the Short-Form Health Survey-36.
| WHICH STUDY POPULATION IS

SUITABLE?
The SMILE/MOSES manual states that the program "is suitable for all epilepsy patients (aged 16 or older), irrespective of the kind and severity of their epilepsy. Participants with long-standing epilepsy will meet with others who were confronted with their diagnosis only recently. Or participants, who are seizure-free or have very few seizures, are faced with patients whose epilepsy has been resistant to therapy so far." 6 Therefore, no minimal seizure frequency was required to participate in the MOSES RCT; 27.1% of the control group and 20.4% of the treatment group had no seizures in the past 6 months (see Table 1 in May and Pfäfflin 3 ). The SMILE RCT 1 indicated that in the MOSES RCT, "42% had no seizure in the prior 6 months" (p. 12). This is not correct. Participation in the SMILE RCT was restricted to adults with chronic epilepsy having ≥2 seizures in the prior 12 months, which is not in accordance with the original inclusion criteria for attendance in the program. Additionally, psychiatric comorbidity and duration of epilepsy were higher in the SMILE RCT compared to the MOSES RCT. Thus, patient groups in the MOSES and SMILE RCTs are not comparable. This raises the question of whether efficacy of educational programs may be related to investigated patient groups.
| WHICH ANALYSIS SET IS
SUITABLE?
The MOSES evaluation used a per-protocol approach. However, only eight (3.2%) of 250 patients were excluded due to protocol violations (including one patient who attended the MOSES program only 1 of 2 days). Hence, all included patients had attended the 2-day program. Missing values of noncompleters (patients who did not complete the questionnaire at baseline or 6 months later) were not replaced.
It is criticized in the SMILE study that "this approach no longer retains the benefits of randomization and raises the possibility of selection bias. Consistent with this, the median duration of epilepsy was significantly lower in the MOSES intervention arm once noncompleters were dropped from the trial sample (MOSES control: 18.2 years, MOSES intervention: 13.5 years, P = 0.034)." 1 We were aware of the possibility of selection bias and therefore compared demographic and clinical data and outcome measures in patients of the treatment and waiting groups at baseline (per-protocol approach). However, only duration of epilepsy differed significantly between the groups. It cannot be excluded that this was "significance by chance" due to the large number of variables tested. Furthermore, the groups differed in epilepsy duration already at baseline, before noncompleters were excluded (17.4 vs 14.7 years, P = 0.044). Thus, the difference in epilepsy duration between groups in the per-protocol analysis was not caused by the exclusion of noncompleters.
The SMILE RCT analyzed outcomes according to the intention-to-treat principle. Therefore, all patients randomized to the intervention group were evaluated as if they had actually attended the educational program. However, 54 (26.3%) patients randomized to the intervention group did not attend the SMILE program (no session completed) and only 126 (61.5%) completed all four sessions.
Therefore, one might ask whether a modified intentionto-treat approach including only patients who completed at least one session would not have been more appropriate.
The authors did not report whether there were any significant differences between groups at baseline in the SMILE RCT (using an intention-to-treat approach and multiple imputation of missing values). One would assume no differences. However, for example, the secondary endpoint anxiety (Hospital Anxiety and Depression Scale) seems to differ significantly between intervention and control groups (9.0 ± 5.0 vs 7.8 ± 4.8) at baseline.
| CONCLUSION
Improvement in knowledge and coping with epilepsy are essential aims of the educational program MOSES/SMILE. Thus, outcome measures should cover these aims. Regrettably, this was not the case in the SMILE evaluation. However, in-depth interviews of participants indicated that SMILE has favorable effects on knowledge and coping in therapy-resistant patients with epilepsy.
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